Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes

Mixed-meal tolerance tests (MMTTs) are used in clinical trials to evaluate β-cell function in patients with new-onset type 1 diabetes (1,2). Some trials use a 4-h MMTT, whereas others use an abbreviated (2-h) protocol to reduce investigator and subject burden. In the T1DAL (Inducing Remission in Type 1 Diabetes With Alefacept) trial of patients with new-onset type 1 diabetes, the primary analysis using the 2-h test failed to reach statistical significance ($P = 0.065$), but a 4-h test did ($P = 0.019$) (3). We investigated the effect of abbreviating the test using data from 186 patients participating in three clinical trials conducted by the Immune Tolerance Network (3–5). Trials were approved by institutional review boards at the participating institutions. Written informed consent or assent was obtained.

Each patient contributed up to three 4-h MMTTs, conducted yearly, for a total of 506 paired 2- and 4-h observations. For this analysis, the 4-h assessment, which captures more of the complete hormonal response, was selected as the reference. The percent of the total 4-h C-peptide area under the curve (AUC) captured in the first 2 h ranged from 28% to 72%. Mean AUCs (mAUCs) were computed as 2- or 4-h AUCs divided by duration, 120 or 240 min, respectively. The correlation between the 2- and 4-h mAUCs was 0.98. Generally, the variability of the 2-h test was greater than that of the 4-h test (Fig. 1A). After adjusting for baseline, however, the variability was similar.

The standardized difference (Sdiff), the “distance” between the 2- and 4-h mAUCs measured in SD units, was used to evaluate associated factors. Both positive and negative differences exceeding 1 SD were observed for peak C-peptide values $\geq 0.6$ pmol/mL (Fig. 1B). For peak values exceeding 1.6 pmol/mL, however, the 2-h mAUC generally overestimated the 4-h mAUC. Moreover, the 2-h mAUC generally overestimated the 4-h assessment when the time to peak was $< 120$ min and vice versa for times $> 120$ min (Fig. 1C).

As C-peptide levels may be associated with time, age, and treatment, we evaluated their impact on Sdiff. For low baseline Sdiffs, Sdiffs tended to increase over time and vice versa for high baseline values. For some individuals, however, Sdiffs were highly variable over time (Fig. 1D). Among untreated subjects, the distribution of Sdiffs among adults was shifted downward compared with pediatric subjects, who also had some extremely high values (Fig. 1E). At month 12, 56% of observations from the drug-treated subjects in the AbATE (Autoimmunity-Blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes) study had a positive difference between 2-h and 4-h mAUCs compared with 27% of observations for control subjects; the treatment effect was underestimated using the 2-h mAUC (Fig. 1F). In START (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), the treatment effect was underestimated with a 2-h test (data not shown).

Our findings may have important implications for designing studies. Because the impact of the abbreviated test is differential over time and by age and treatment groups, estimates and significance tests for 2- and 4-h assessments may be inconsistent. The variability of the C-peptide mAUCs may also affect sample size needs. Consideration of the methods used to measure C-peptide

Karen D. Boyle,¹ Lynette Keyes-Elstein,¹ Mario R. Ehlers,² James McNamara,³ Mark R. Rigby,⁴ Stephen E. Gitelman,⁵ Lia J. Weiner,¹ Kristen L. Much,¹ and Kevan C. Herold⁶

References:
¹Rho Federal Systems Division, Chapel Hill, NC
²Immune Tolerance Network, San Francisco, CA
³National Institute of Allergy and Infectious Diseases, Rockville, MD
⁴Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Spring House, PA
⁵Department of Pediatrics, University of California, San Francisco, San Francisco, CA
⁶Department of Immunobiology and Internal Medicine, Yale University, New Haven, CT

Received 22 September 2015 and accepted 26 February 2016.

Clinical trial reg. nos. NCT00129259, NCT00965458, and NCT00515099, clinicaltrials.gov.

© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Figure 1—Analysis of 2- and 4-h C-peptide AUCs during MMTTs. The C-peptide AUC was computed for 2 and 4 h at baseline and at months 12 and 24 using the trapezoidal rule; mAUCs were computed by dividing AUCs by the duration of the test, 120 or 240 min, as indicated. Sdiff equals the 2-h mAUC minus the 4-h mAUC in SD units. Within each trial, the values below the lower limit of detection were either assigned a value of one-half of the lower limit of detection (START and T1DAL) or 0 (AbATE). Only available data were used in these analyses; missing MMTTs were not imputed.

### Table A: All subjects with a baseline assessment

|         | n  | Mean | SD  | RMSE |
|---------|----|------|-----|------|
| Baseline| 2hr mAUC | 180 | 0.78 | 0.37 |
|         | 4hr mAUC | 180 | 0.78 | 0.32 |

### Table B: Pooled controls over time

|         | n  | Mean | SD  | RMSE |
|---------|----|------|-----|------|
| Baseline| 2hr mAUC | 58  | 0.76 | 0.39 |
|         | 4hr mAUC | 58  | 0.76 | 0.32 |
| Month 12| 2hr mAUC | 52  | 0.51 | 0.45 | 0.26 |
|         | 4hr mAUC | 52  | 0.50 | 0.38 | 0.26 |
| Month 24| 2hr mAUC | 48  | 0.35 | 0.50 | 0.26 |
|         | 4hr mAUC | 48  | 0.34 | 0.45 | 0.28 |

### Table C: Active treatment at month 12 by study

|         | n  | Mean | SD  | RMSE |
|---------|----|------|-----|------|
| AbATE   | 2hr mAUC | 51  | 0.63 | 0.46 | 0.30 |
|         | 4hr mAUC | 51  | 0.61 | 0.41 | 0.28 |
| START   | 2hr mAUC | 35  | 0.67 | 0.38 | 0.29 |
|         | 4hr mAUC | 35  | 0.67 | 0.38 | 0.30 |
| T1DAL   | 2hr mAUC | 29  | 0.89 | 0.52 | 0.29 |
|         | 4hr mAUC | 29  | 0.87 | 0.44 | 0.28 |

Figure 1A: 2- to 4-h C-peptide mAUC estimates. Data from all control subjects over 24 months are shown and from drug-treated subjects at month 12. Root mean square error (RMSE) was derived from ANCOVA models controlling for baseline mAUC. Six subjects without baseline data were excluded. For active treatment groups at baseline and month 24, SDs for 2-h tests were greater than for 4-h tests (data not shown) except for T1DAL at month 24 where SDs were 0.51 and 0.52 for 2-h and 4-h tests, respectively. B: Sdiff by peak C-peptide value. The peak C-peptide value is the observed measurement with the highest value. The solid line shows the average trend. C: Sdiff by time at peak C-peptide point. The top and bottom of each box represent the...
responses is important in clinical trial design.

Funding. These analyses were performed by Rho, the statistical and clinical coordinating center for the Immune Tolerance Network trials and the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) Division of Allergy, Immunology, and Transplantation (HHSN272200800029C and 1UM2-AI-117870). The three clinical trials from which data were used were conducted by the Immune Tolerance Network and sponsored by the NIAID under award numbers NO1-AI-15416 and UM1-AI-109565. Additional funding for the trials was provided by the JDRF and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This publication was supported by NIH National Center for Research Resources University of California, San Francisco, Clinical & Translational Science Institute grant UL1-TR-000004. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. All authors contributed to the analyses or discussion used in this letter. K.D.B., L.K.-E., L.J.W., and K.L.M. performed the analyses. K.D.B. and K.C.H. wrote the letter. K.D.B., L.K.-E., M.R.E., J.M., M.R.R., S.E.G., L.J.W., K.L.M., and K.C.H. contributed to discussion and reviewed and edited the letter. K.D.B. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. This work was presented at the 14th International Congress of the Immunology of Diabetes Society, Munich, Germany, 12–16 April 2015, and at the 75th Scientific Sessions of the American Diabetes Association, Boston, MA, 5–9 June 2015.

References
1. Greenbaum CJ, Beam CA, Boulware D, et al.; Type 1 Diabetes TrialNet Study Group. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012;61:2066–2073
2. Steele C, Hagopian WA, Gitelman S, et al. Insulin secretion in type 1 diabetes. Diabetes 2004;53:426–433
3. Rigby MR, DiMeglio LA, Rendell MS, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 2013;1:284–294
4. Gitelman SE, Gottlieb PA, Rigby MR, et al.; START Study Team. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2013;1:306–316
5. Herold KC, Gitelman SE, Ehlers MR, et al.; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013;62:3766–3774